Content area
Full text
Addendum to: EMBO Mol Med (2019) 11: e11115. DOI 10.15252/emmm.201911115 ¦ Published online 3 November 2019
The authors recently contacted the journal to inform the editor of changes they discovered in the isogenic control (HCMrep) clone derived from the hypertrophic cardiomyopathy (HCM)-specific hiPSC clone.
After the initial publication, the authors performed a new genomic sequencing of the HCM and HCMrep hiPSC clones, which revealed in the HCMrep an additional point mutation (T>C, blue in Fig 1) next to the CRISPR/Cas9-mediated repair of the HCM gene variant (T>C, violet). This heterozygous mutation (c.697+2T>C) is an on-target artifact of CRISPR/Cas9 gene editing and is located in the donor splice site...